Agoracom Blog Home

Archive for the ‘Medical Marijuana Stocks’ Category

MedX Health Corp. $MDX.ca Bolsters Global Footprint and Adds Renowned Skin Care Expert to Senior Leadership Team $DMTK $ICAD $PLSE $SRTS

Posted by AGORACOM-JC at 9:16 AM on Monday, September 21st, 2020
Home - MedX Health
  • Announced the appointment of veteran healthcare industry executive Naman Demaghlatrous as Managing Director, Europe, Middle East & Africa (“EMEA”), effective immediately
  • Additionally, Chantal Ward, RN has taken a permanent position with the Company as Director, Dermatological Services

MedX Health Corp. (“MedX”) (TSX-V: MDX) is pleased to announce the appointment of veteran healthcare industry executive Naman Demaghlatrous as Managing Director, Europe, Middle East & Africa (“EMEA”), effective immediately. Additionally, Chantal Ward, RN has taken a permanent position with the Company as Director, Dermatological Services.

“Naman’s extensive background in healthcare and medical devices, along with his deep relationships will allow us to accelerate business development opportunities in the region,” said Mike Druhan, President of Dermatological Products & Services. “Chantal is an internationally recognized and respected leader in the dermatology and aesthetics spaces, bringing credibility to our offerings and putting an impressive opinion leader network at our disposal.”

Mr. Demaghlatrous has more than 20 years of experience in the healthcare industry, including roles with medical device and pharmaceutical companies leading business strategy, international product licensing, business development and operations. He has proven expertise in leading organizations through start-up to rapid growth, expansion and value creation with companies such as Medtronic, Pediapharm, Johnson & Johnson and Atfal Pharma. Mr. Demaghlatrous will play an integral part in MedX’s revenue growth prospects by securing European, Middle Eastern and African partnerships for MedX’s skin assessment telemedicine technology. Initially supporting the roll out and expansions in the Netherlands, Spain and Turkey, he will also be responsible for securing joint ventures and partnerships across the EMEA Region.

“Helping patients access an e-consult on suspicious lesions or moles quickly and easily means better treatment and better outcomes,” noted Mr. Demaghlatrous. “There is already significant interest and traction across the region and I am expecting substantial growth over the next six to nine months.”

Chantal Ward RN, a Diploma Nurse Graduate from an operating room background, has 20+ years’ experience as a clinical trainer of advanced medical aesthetic equipment and technology. Her expertise is acknowledged across Canada and around the world, where she has provided guidance and training to hundreds of medical aesthetic professionals. Ms. Ward is Co-Founder of Clarity MedSpa & Laser Centre, Toronto and has significant experience with MedX’s SIAscopy on DermSecure™.

“I have been using this device in my clinic for several years and have caught multiple melanomas,” said Ms. Ward. “The device is easy to use and the ability to have a dermatologist provide a remote e-consult, within 72 hours, is critical. Early detection is the key to a successful patient outcome.”

“MedX is in full commercialization mode and Naman and Chantal are welcomed additions to our team. Recently, Damon Goodwin and Nick Hoffman have been announced to our senior management team and we are already feeling their impact. It is a satisfying to know that MedX can attract such seasoned professionals and I strongly believe that is because of the strength of our technology offering and the culture we have built,” further commented Mr. Druhan.

Currently, between two and three million non-melanoma skin cancers and 300,000 melanoma skin cancers occur globally each year. One in every three cancers diagnosed is a skin cancer and, according to Skin Cancer Foundation statistics, one in every five people will develop skin cancer in their lifetime. The global demand for SIAscopy on DermSecure™ will continue to increase with the growth of telemedicine and as early detection is recognized as the way to optimize survival and reduce healthcare costs.

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy on DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200921005178/en/

Contacts:

Mike Druhan, President, Dermatological Services
MedX Health Corp
Tel: 905-599-7852

$APPB Applied Biosciences interviewed by Upticknewswire for The First time on the Stock Day Radio podcast and Discuses the Growth of Their CBD Product Lines $HTI

Posted by AGORACOM-Eric at 7:06 AM on Monday, November 26th, 2018

LOS ANGELES, CA / ACCESSWIRE / November 26, 2018 / Applied BioSciences Corp. (OTCQB: APPB) is a diversified cannabinoid therapeutics company that specializes in the medical,bioceutical, and pet health industries. The President of Applied BioSciences, Chris Bridges, joined Stock Day’s Everett Jolly for the first time to discuss the Company’s newly expanded product line, as well as their goals for growth going forward.

Jolly began the interview by asking Bridges for a little bit of background information on the Company, as well as himself. Bridges responded, “We’re a diversified company focused primarily on the CBD market. We have several different brands under our umbrella.” Bridges went on to explain that these included consumer-based brands and their product lines, as well as Herbal Pet, which is a pet-focused brand.

Speaking of his own background, Bridges the stated, “Primarily my background is as a tech entrepreneur and in the payment space. I have been building companies since I was in my early 20’s, and came onboard with Applied BioSciences about two years ago and have been really excited about building this company.”

Jolly noted the crowded CBD industry given the recent popularity of these products and then asked, “What makes your CBD products so special?” Bridges expanded on the uniqueness of his product line and explained, “What makes our products special is that they are completely organic and free of poisons and pesticides. We have done a great job at creating the best-in-class CBD products out there.”

Bridges then discussed the estimated growth of the CBD market, noting that by 2022 this industry will be worth around $22 Billion. Bridges added, “What drove us to create these product lines was focusing on specific targets. We’re looking to achieve products that really solve specific problems.”

The interview then turned to the discussion of one of the Company’s brands, Herbal Pet, which has been growing steadily as a pet line under Bridge’s leadership. Jolly inquired, “When is this brand really going to come to fruition and how big is the demand for this segment?”

Bridges responded, “We’re starting to push the direct to consumer sales, as well as wholesale for the products. There’s a massive and explosive growth for pet-oriented products around CBD. We’re really excited about the potential of this one. It’s one of the biggest growing brands under our umbrella.”

Bridges then discussed the Company’s recently closed deal for financing in the amount of $1 Million and explained that they intend to use the funds for the pure growth and expansion of their umbrella brands and their product lines.

The interview closed with Bridges sharing that the team behind Applied BioSciences is truly special and incredibly experienced in the growth of successful companies. Bridges then continued, “We’re building a great platform and expect to be one of the great leaders in this industry.”

To learn more about Applied BioSciences Corp. listen to the full podcast: https://upticknewswire.com/featured-interview-president-chris-bridges-of-applied-biosciences-corp-otcqb-appb/.

About Applied BioSciences Corp.:

Applied BioSciences Corp. (www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical,bioceutical and pet health industry. As a leading company in the CBD and Pet health space, the company is currently shipping to the majority of US states as well as to 5 International countries. The company is focused on select investment, consumer brands, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.

The company has several strategic partnerships and investments currently in place and is actively pursuing additional partnerships and strategic growth opportunities.

Contact:

Email: [email protected] or [email protected]

To be added to the Applied BioSciences email distribution list, please email [email protected]ocorp.com with APPB in the subject line. Official Website: www.appliedbiocorp.com

$APPB Applied Biosciences Enters the Vape Inhaler Market $HTIM

Posted by AGORACOM-Eric at 9:06 AM on Wednesday, November 7th, 2018

https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564626/hub/APPB_logo.png

  • Expanded product line and launched an alternative vape inhaler technology using water vapor and natural flavors.
  • Products will be sold on the Remedi website (www.remedishop.com)
  • Global e-cig and vaporizer market has been recently valued at $9.0 billion
  • Applied BioSciences products are USDA NOP certified organic, non-GMO, vegan, paleo, gluten-free, sugar-free and THC-free.

LOS ANGELES, CA / ACCESSWIRE / November 7, 2018 / Applied BioSciences Corp. (OTCQB: APPB), a diversified cannabinoid therapeutics company focused on the medical,bioceutical and pet health industries, announced that it has expanded its product line and launched an alternative vape inhaler technology using water vapor and natural flavors. These products will be sold on the Remedi website (www.remedishop.com) and in select retail locations in the U.S. and internationally.

The global e-cig and vaporizer market is one of the fastest growing consumer markets and has been recently valued at $9.0 billion and expected to grow at a CAGR of 23.6% and reach $49 billion by the end of 2024, according to Research Nestor (www.researchnester.com).

The Remedi Plus Therapeutic Vapor Inhaler contains a revolutionary recipe of steam-distilled essential oils and flower essences uniquely blended with CBD Isolate. Generating a robust, yet smooth and clean, inhalable vapor, the aromatherapeutic effects are instantaneous, followed by a calming and effective dose of CBD. Watermelon, Mint, Rose & Ylang Ylang flower deliver a crisp and energetic, uplifting effect, while the Green Tea, Vanilla, Chamomile, Rose and Ginger offer the user a calming, anti-anxiety, sleep-aid effect. Free of additives such as MCT, PG or VG. The Remedi Plus product line has been crafted with just simple flavored waters by nature and blended with CBD in vapor form.

The hardware of the unit itself is comprised of 100% FDA-Approved materials. Applied Biosciences uses organic ingredients and formulations that were created to target common ailments in the health and wellness industry for anyone who is open to trying hemp derived products. The products use industrial hemp as an input to produce high-quality CBD for a variety of health and wellness products.

”Remedi continues to be at the forefront of the consumer and prosumer cannabinoid market, first using organically grown plants, without pesticides or herbicides as our main ingredient and now quickly and easily providing consumers with a variety of tinctures, topical creams and now an alternative vape technology. As Applied BioSciences continues to expand our product lines in select specialty and retail stores, people will also be able to visit remedishop.com to find a holistic health and wellness alternatives that best suit their lifestyle,” commented Chris Bridges, President of Applied BioSciences Corp.

Applied BioSciences products are USDA NOP certified organic, non-GMO, vegan, paleo, gluten-free, sugar-free and THC-free. The products are formulated with organic 99%+ pure cannabidiol along with our proprietary blend of certified organic botanicals, herbals, and essential oils to further optimize bioavailability.

About Applied BioSciences Corp.:

Applied BioSciences Corp. (www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical, bioceutical and pet health industry. As a leading company in the CBD and Pet health space, the company is currently shipping to the majority of US states as well as to 5 International countries. The company is focused on select investment, consumer brands, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.

The company has several strategic partnerships and investments currently in place and is actively pursuing additional partnerships and strategic growth opportunities.

Contact:

Email: [email protected] or [email protected]

To be added to the Applied BioSciences email distribution list, please email [email protected] with APPB in the subject line.

Official Website: www.appliedbiocorp.com

Brands:

www.remedishop.com

www.herbalpet.com

Follow us:

Facebook @remedicbd & @HerbalPetMeds

Instagram @remedishop & @herbal_pet

Twitter @remedishop & @herbal_pet

 

$APPB Applied Biosciences Enters into $1 Million Equity Financing Agreement with Triton Funds

Posted by AGORACOM-Eric at 9:40 AM on Wednesday, October 31st, 2018

https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564626/hub/APPB_logo.png

    • Stock Purchase Agreement with Triton Funds, LP for up to $1,000,000 of registered APPB common stock
    • Provides growth funding to accelerate APPB growth in the consumer and pet CBD market
    • APPB products are USDA NOP certified organic, non-GMO, vegan, paleo, gluten-free, sugar-free and THC-free.
    •  Products are formulated with organic 99%+ pure cannabidiol along with our proprietary blend of certified organic botanicals

(October 31, 2018) Los Angeles, CA – Applied BioSciences Corp. (OTCQB: APPB), a diversified cannabinoid therapeutics company focused on the medical, bioceutical and pet health industries, announced that it has entered into a Common Stock Purchase Agreement with Triton Funds, LP, a Delaware limited partnership (“Triton Funds”), in which Triton Funds has agreed to purchase up to $1,000,000 of registered common stock of the Company in connection with a separate Registration Rights Agreement.

“We are excited to be working with a cutting-edge organization focused on financing emerging growth companies. Our agreement with Triton Funds is highly advantageous to the company in that it provides growth funding to accelerate our rapid growth in the consumer and pet CBD market, while affording Triton Fund a significant long-term upside opportunity through their equity investment. It’s beneficial for everyone, especially our shareholders who will benefit by the significant investment Triton Funds is making in our company.” Stated Chris Bridges President.

“Applied BioSciences is a company that has a very strong reach in its field. With a management team like Chris Bridges and JJ Southard we are confident they can capitalize on their visions and goals” said Yash Thukral, Founder at Triton Funds LLC.“ We are excited to be working with a company who challenges the limits of its industry.”

“At Triton Funds we dive in and invest in companies that make a positive impact in evolving spaces, such as the CBD industry. Applied BioSciences does exactly that by diversifying themselves amongst different CBD and hemp products, ranging from creams and oils to capsulses and vapes. Moreover, with a strong management team and great financials, we expect to grow and evolve with Applied BioSciences.” Said Ashkan Mapar

Applied BioSciences products are USDA NOP certified organic, non-GMO, vegan, paleo, gluten-free, sugar-free and THC-free. The products are formulated with organic 99%+ pure cannabidiol along with our proprietary blend of certified organic botanicals, herbals and essential oils to further optimize bioavailability.

About Applied BioSciences Corp.

Applied BioSciences Corp. (www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical, bioceutical and pet health industry. As a leading company in the CBD and Pet health space, the company is currently shipping to the majority of US states as well as to 5 International countries.  The company is focused on select investment, consumer brands, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.

The company has several strategic partnerships and investments currently in place and is actively pursuing additional partnerships and strategic growth opportunities.

About Triton Funds 

Triton Funds, La Jolla, California, was started by three undergraduate students from Southern California aspiring to create an investment fund with a ‘millennial touch’. It began on the streets of La Jolla in search of investors willing to back our idea of a student-run fund that creates a greater sense of community through investments in local companies and entrepreneurs, philanthropy, and guidance to fellow college students interested in the finance field. As a result, local limited partners, coupled with the support of our advisory board, established Triton Funds, creating real-world opportunities for college students to guide its investments in growing companies. For more information, visit, https://www.tritonfunds.com.

Contact

Email: [email protected]  or [email protected]

To be added to the Applied BioSciences email distribution list, please email [email protected] with APPB in the subject line.

Official Website: www.appliedbiocorp.com

Brands:

www.remedishop.com

www.herbalpet.com

www.canagel.com

Follow us:

Facebook @remedicbd & @HerbalPetMeds

Instagram @remedishop & @herbal_pet

Twitter @remedishop & @herbal_pet

Canada Running Short Of #Marijuana After Legalization $BOG.ca $NBUD.a $MCOA $TBP.ca $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 9:54 AM on Monday, October 22nd, 2018

  • Just two days after it legalized the sale and personal use of recreational marijuana on Oct. 17, Canada has found itself suffering from a shortage of the commodity
  • Canadian cannabis producers and stores apparently underestimated the huge surge in demand for cannabis following its legalization.

Oct 22, 2018 06:47 PM

The United States might be in for the same surprise when it legalizes the use of recreational marijuana or cannabis in the future.

Just two days after it legalized the sale and personal use of recreational marijuana on Oct. 17, Canada has found itself suffering from a shortage of the commodity. Canadian cannabis producers and stores apparently underestimated the huge surge in demand for cannabis following its legalization.

Under the new law, Canadian citizens will be allowed to carry up to 30 grams of cannabis in public and each household will be able to grow up to four marijuana plants.

Statistics Canada, the country’s national statistics agency, estimated that 5.4 million Canadians will buy cannabis from legal dispensaries in 2018. That’s about 15 percent of the population. In addition, some 4.9 million Canadians already smoke weed. These projections included a boost from legalization but were still off the mark due to the high demand for cannabis.

Bill Blair, who led the government’s cannabis legalization program, said the country is unable to supply enough to meet demand. He said the government expected “certain strains might run out and there would be a bit of a run on supply.”

Cannabis supply began running low on Oct. 19. The supply dearth saw retailers are turning people away because they’d run out of stock.

The Ontario Cannabis Retail Corporation, the sole legal retailer of recreational cannabis in the province of Ontario, said some cannabis items are unavailable on its website. It said given the scarcity of cannabis products across Canada, it expects “significant” short-term supply problems.

Cannabis retailers in Alberta and Prince Edward Island said certain cannabis products quickly sold out online after vigorous business on their cannabis sales websites on the first day of legalization. Experts said the supply shortage situation is the same across Canada.

Experts said the shortage of cannabis brings with it the risk Canada might soon run out of practically its entire inventory of cannabis products. The situation is due to supply and demand with many users stocking-up due to worries there might not be enough stock in the stores over the next few weeks.

Cannabis demand is under threat because supply didn’t ramp up to meet demand, said marijuana advocate Steven Stairs. He expects the government to step in and try to ensure supply by mitigating regulation and taxation.

The Cannabis Commerce Association of Canada said most of the cannabis produced in Canada right now doesn’t come from the black market but rather from medically licensed growers, or the grey market. These licensed growers weren’t able to ramp-up production in time to meet demand because weed wasn’t legal at the time so there was no sense in boosting production.

Growers also held off on planting more weed because licenses allowing them to do so weren’t available before Oct. 17. Those who applied on Oct. 17 are still waiting for their applications to be processed.

Source: http://en.businesstimes.cn/articles/104225/20181022/canada-running-short-marijuana-legalization.htm

$BOB.ca Bougainville Ventures to Purchase Additional Property in Washington State $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-Eric at 1:07 PM on Thursday, October 18th, 2018
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564641/hub/681747-5720_copy_2.jpg
  •  Entered into an agreement with Green Venture Capital Corp., to purchase the balance of a 4 acre property in Oroville, Washington.
  • Future plans for the property include multi-tenant greenhouse structures.
  • A report by the Rand organization suggests that there are currently up to 650,000 recreational marijuana users in Washington State, worth approximately $1.25 – $1.5 Billion USD in annual sales.

 Vancouver, BC, Canada – October 17, 2018, BOUGAINVILLE VENTURES INC. (“Bougainville” or the “Company”) (CSE:BOG) (“Bougainville” or the “Company”) is pleased to announce it has entered into an agreement with Green Venture Capital Corp., to purchase the balance of a 4 acre property in Oroville, Washington.

The Company currently owns a one acre parcel of land that is occupied by a Tier -3, I-502 tenant. This transaction will add another 3 acres to the Oroville Campus. Once this transaction is completed the Company will have purchased the 4 acre parcel of land in Whatcom County, Washington State for a total purchase price of $350,000.00 USD. The Company now has up to 30 days to complete its due diligence. During this due diligence period the Company will work with its architect to develop future plans for the property that will include multi-tenant greenhouse structures.

The property meets all the Company’s criteria for its planned expansion into Washington State on it Oroville Campus. The property is permitted for both agricultural and light industrial production and processing uses, and currently contains two buildings totaling 1,700 sq. ft. and a 1,000 sq. ft. workshop/garage with sufficient room for expansion.
Andy Jagpal, President of Bougainville, commented that, “The addition of this property in Washington State will help the Company achieve its strategic goals and objectives to facilitate expansion of its Oroville Campus.”

About the Washington I-502 Marijuana Market In November 2012, the Washington State Liquor Control Board (WSLCB) passed Initiative 502 (I-502) pursuant to a vote by the people of the State of Washington. I-502 authorized the WSLCB to regulate and tax recreational marijuana products for persons over twenty-one years of age and thereby created a new industry for growing, processing and selling of Washington State-regulated recreational marijuana products. A recent WSLCB commissioned report by the Rand organization suggests that there are currently up to 650,000 recreational marijuana users in Washington State, worth approximately $1.25 – $1.5 Billion USD in annual sales.

About Bougainville Ventures, Inc.  Bougainville provides cannabis infrastructure and seed-to-sale services to I-502 tenant-growers leasing greenhouse facilities space and providing fully built-out, turnkey solutions and ancillary services including processing, cannabis expertise and marketing and sales resources. Greenhouse canopies provide a 50% saving in cultivation cost. Bougainville has 30,000 sq.ft., in near production in Oroville, WA.
For more information please visit: http://bougainvilleinc.com/

On behalf of the Board of Directors BOUGAINVILLE VENTURES INC.

Andy Jagpal, CEO and Director

For further information, please contact Andy Jagpal at [email protected] or 1-844-734-8420

CLIENT FEATURE: AppliedBiosciences: Diversified in Multiple Areas of Hemp and CBD Industry $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-Eric at 9:03 AM on Thursday, October 18th, 2018

https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564626/hub/APPB_logo.png

Why AppliedBiosciences?

    • Diversified company focused on multiple areas of the Hemp and CBD Industry
    • Focused on opportunities in the recreational, health and wellness, nutraceutical and media industries
    • Several Strategic Partnerships in place

Multiple Product Lines:

Hub On AGORACOM

FULL DISCLOSURE: AppliedBiosciences is an advertising client of AGORA Internet Relations Corp.

No. 1 Wall Street #pot analyst says the #marijuana market will be much bigger than she first thought $BOG.ca $NBUD.ca $MCOA $APPB

Posted by AGORACOM-JC at 10:53 AM on Friday, October 12th, 2018
  • The cannabis industry’s rapid evolution and new strategic partnerships with mainstream brands reveal a far larger possible market for legal marijuana than investors and analysts first anticipated, according to Cowen.
  • Cowen’s Vivien Azer nearly triples her 12-month price forecast on Canadian marijuana producer Tilray this week to $172 from $62.
  • Recreational use of cannabis in Canada becomes legal Oct. 17, though each of the country’s 10 provinces will be able to regulate the market within their jurisdiction.

Wall Street’s top pot analyst says marijuana market will be much bigger than she first thought   23 Hours Ago | 00:58

With Canada about to legalize recreational use of marijuana, the industry’s rapid evolution and new strategic partnerships with mainstream brands reveal a far larger possible market for pot than investors and analysts first anticipated, according to Cowen.

“With cannabis, you’re talking about this massive step change in terms of the addressable market,” Vivien Azer said on CNBC’s “Squawk Box” on Wednesday. “You’re bringing a $7 billion illicit market into the legal market and so it does require a different valuation framework.”

Azer, the only pot analyst from a major Wall Street research house, nearly tripled her 12-month price forecast on Canadian marijuana producer Tilray this week to $172 from $62. The new target for the stock, which trades in the U.S. on the Nasdaq, implies more than 30 percent upside from current levels. She also upped her forecast on Canadian pot company Canopy Growth.

Supply remains critical issues for cannabis companies, says analyst   8:17 AM ET Wed, 10 Oct 2018 | 01:51

Just how big the market will get is tough to put a number on right now, but Azer cites a cannabis executive who estimated the market could be one day worth $500 billion.

“Our broader, big picture view of cannabis goes beyond the adult use launch in Canada,” she wrote in a report this week. “Rather, we believe this is the first step toward the establishment of cannabis as a key functional ingredient touching multiple consumer categories with four key verticals: adult use, beauty and nutraceuticals, OTC pain and sleep, and pharmaceuticals.”

Recreational use of cannabis in Canada becomes legal Oct. 17, though each of the country’s 10 provinces will be able to regulate the market within their jurisdiction independent of Ottawa.

While it’s still early days for the marijuana business, the first signs of its broader applications are easily recognized.

Tilray shares, which are up more than 650 percent since their July IPO, posted one of their best days ever mid-September after the company announced approval from the Drug Enforcement Administration to import weed to the U.S. for medical research.

In a move likely foreshadowing broader pharmaceutical application, the company will work with the University of California San Diego Center for Medicinal Cannabis Research to study the safety, tolerability and efficacy of marijuana for a neurological disorder.

“If this study can identify cannabinoids as a potential treatment for patients suffering from essential tremor, we can conduct further research and potentially provide alternative effective methods of relief for the high numbers of patients with Essential Tremor,” said Catherine Jacobson, director of clinical research at Tilray.

The globe’s major alcohol companies have also wasted no time exploring joint ventures with a handful of lucky cannabis producers.

Alcohol vs. Cannabis use in the U.S.

Constellation Brands recently increased its investment in Canopy Growth with a 9.9 percent stake in the company, granting the Corona beer brewer a foothold in an industry it expects to soon be legal in the United States.

“We think that we’re by far the best company in the world — or in the best position in the world of any company — to capitalize on what is absolutely without a doubt going to be a huge market over the next 10 years, hundreds of billions of dollars,” Constellation CEO Robert Sands said in the company’s earnings call Thursday.

“We expect to reap the benefits of our cannabis investment, which we see as being incremental to our core beer, wine and spirits portfolio,” he added.

Richard Lautens | Toronto Star | Getty Images
Dried plants are processed and trimmed by hand. A a state-of-the-art fully automated medical marijuana production facility is in a nondescript building in Scarborough.

And while the upside for Constellation appears obvious, the benefit is two-fold. A check from one of the world’s largest brewers is a welcome influx of capital for a handful of companies whose success will likely be defined by their ability to raise capital and scale production.

“Given the nascent stage of global cannabis, we believe that revenue growth should serve as the primary valuation methodology,” Cowen’s Azer said in her note. Specifically, Azer said her primary measurement when drawing price estimates is enterprise value divided by sales, divided by revenue growth, akin to a traditional price/earnings growth ratio.

Some Wall Street firms cover the pot stocks, but none the size of Cowen. It’s still an emerging industry.

To be sure, the spike in certain pot stocks — combined with a limited count of floating shares for some companies — has left stocks like Tilray and Canopy with lofty valuations and rampant volatility.

Tilray has about 93 million shares outstanding, but the float — those shares actually available for trading — is just 21 million, according to FactSet.

Tilray’s 2020 P/E ratio, meanwhile, is currently 300; Canopy’s is 125. Tilray’s stock price has posted no less than 12 days of double-digit moves on percentage basis in the last month.

“There have been no shortage of recent catalysts to spur market and investor interest,” Azer said. “As such, volatility should be seen as a natural occurrence in the cannabis market, and not dissimilar to other nascent industries.”

https://www.cnbc.com/2018/10/10/top-pot-analyst-says-weed-market-bigger-than-first-thought.html

Health Canada Reclassifies Tetra Bio-Pharma’s $TBP.ca Inhalation Device Making it Eligible for Reimbursement $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:20 AM on Thursday, September 13th, 2018

Logo tetrabiopharma rgb web

  • Health Canada has re-classified the inhalation pipe device used in the delivery of its PPP001 cannabis drug to a Class 2 Medical Device
  • The reclassification will help pave the way towards reimbursement for patients; a key element to patient access and care
  • Significance of this decision is such that if PPP001 is approved by Health Canada, both the prescription drug and the inhalation device will be eligible for insurance coverage by private and provincial public insurance plans

ORLEANS, Ontario, Sept. 13, 2018 – Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation“) (TSX VENTURE: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, announced today that Health Canada has re-classified the inhalation pipe device used in the delivery of its PPP001 cannabis drug to a Class 2 Medical Device.  The reclassification will help pave the way towards reimbursement for patients; a key element to patient access and care. The significance of this decision is such that if PPP001 is approved by Health Canada, both the prescription drug and the inhalation device will be eligible for insurance coverage by private and provincial public insurance plans.  Tetra Bio-Pharma is undertaking a Phase III trial with PPP001 treating late stage cancer patients looking to improve quality of life and reduce pain.  The Company also recently announced it is starting a head to head trial to investigate cannabis versus Fentanyl in managing breakthrough cancer pain.

“We are very excited by the reclassification as we believe it will provide patients with a financial benefit in terms of coverage for the device and prescription drug,” stated Dr. Guy Chamberland, Ph.D., Interim CEO and CSO at Tetra Bio-Pharma. “Many cancer patients rely on private and public insurance plans for access to their medication.  This decision by the Government of Canada is an important step forward to facilitating access to cannabis drugs. This coupled with our robust clinical trial program and the evidence we are establishing will support physicians in discussing and recommending this option with their patients.”

Dr. Chamberland further stated, “the lack of scientific data on the safety and efficacy of cannabis is a critical barrier to patient access, and something that Canadian physicians are waiting for before being comfortable to prescribe it. Equally essential is adhering to the highest standards of drug manufacturing as well as the production of the delivery mechanism – something that Tetra is committed to.  There are more than 300,000 registered users of medical cannabis in the country and we can only expect this number to rise.”

Tetra has been a pioneer in the development of several cannabis drugs. To date, the Corporation has completed several safety and pharmacokinetic studies in healthy volunteers obtaining proper dosing information and a clear understanding of the potential cardiovascular and neurological risks to patients. This information is critical to protect public health, and Tetra Bio-Pharma is engaged with Health Canada to comply with the highest drug safety standards.

About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the approval of PPP001, insurance coverage for products being developed, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process including the applications for Orphan Drug Designation, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]

Media Contact
Energi PR
Carol Levine Stephanie Engel
514-288-8500 ext. 226 416-425-9143 ext. 209
[email protected]energipr.com [email protected]

Marijuana Company of America $MCOA Provides Update on CBD Hemp Joint Venture Farming Project in New Brunswick Canada $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 9:35 AM on Thursday, August 30th, 2018

15233 mcoa

  • Provide an update on their CBD hemp farming joint venture in New Brunswick, Canada
  • Dryer Installation – Drying of the biomass is an important first step in the extraction of the cannabinoids from the hemp plant

ESCONDIDO, Calif., Aug. 30, 2018  – MARIJUANA COMPANY OF AMERICA INC. (“MCOA” or the “Company”) (OTC: MCOA), an innovative hemp and cannabis corporation, and its joint venture partner Global Hemp Group Inc. (CSE: GHG) (OTC:GBHPF) (FRANKFURT: GHG) (the “Partners”) are pleased to provide an update on their CBD hemp farming joint venture in New Brunswick, Canada (the “Project”).

Dryer Installation
Drying of the biomass is an important first step in the extraction of the cannabinoids from the hemp plant. The partners are pleased to announce that the Project’s industrial scale dryer from Cann Systems was delivered last week and has now been installed.

The dryer holds multiple bins of material, for a total processing capacity of just over one tonne of fresh hemp biomass per load. Initial testing is in progress and will be completed by the end of this week. Once the biomass has been dried from this year’s harvest, it will be stored until the implementation of the Cannabis Act on Oct. 17, 2018, at which time the biomass can be legally sold for extraction. Health Canada has recently issued a new Class Exemption to the Industrial Hemp Regulations that allows hemp cultivation license holders to legally harvest, dry and store flowers, leaves and branches prior to the passage of the Cannabis Act. Management is currently in discussions with potential offtakers for selling the dried biomass in bulk, as well as exploring potential strategies for toll extraction and the marketing and distribution of processed and refined oils.

Innovation in the Hemp Industry
It is now nearing harvest time at the New Brunswick Hemp Project. To maximize profit, it is important to harvest as much of the higher CBD content flowers and leaves as possible, without undue amounts of the low to no CBD straw (the stalk). This year’s drought has complicated matters as the hemp plants have tended to be shorter than usual, and the weeds are taller as they were able to get a head start before the hemp began growing, although the hemp is still displaying very healthy and weighty inflorescence. These issues that are perceived as problems at they occur, may benefit the hemp plants which tend to produce more biomass as a result of stress from competition with weeds and the effects of the drought.

In order to succeed in the hemp industry, a certain amount of ingenuity and innovation is required more often than not. Our farming group is a good example of this ingenuity. Sometimes repurposing existing equipment on hand will work to achieve the required result. To combat the higher than normal weed height and to maximize the value of the harvest by taking just the most valuable parts of the hemp plant, a small harvesting trial was conducted by one of our farmers using an OXBO bean harvester. The bean harvester is able to strip the plant of all leaves and inflorescence, while picking up very little straw, which is ideal for this year’s crop. Based on the positive results of this trial, the bean harvester will be used to complete the harvest of the entire 125 acres of hemp cultivated under the joint venture project with MCOA this year.

In non-drought years, other harvesting tools will be required and the innovative farmers of our group have already begun strategizing on potential solutions that will be applicable next year when the Partners move forward with an aggressive expansion strategy to significantly increase CBD acreage as well as fully exploit the whole hemp plant and process the straw for industrial applications.

New Research Collaboration
The drought in northeast New Brunswick has not affected all fields uniformly. One of our fields is reported by DAAF field agrologists as “one of the finest of the province”. Aside from the obvious economic benefit in terms of increased yields, this field offers the opportunity to contrast high and low performing plants of a given variety in the same location, shedding some light on the role of plant nutrition in explaining the performance of hemp plants. Dr. Ron Smith from University of New Brunswick will spearhead a research project focused on the issue. The Partners and the National Research Council have committed to provide financial support for the study.

About Marijuana Company of America, Inc.
MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™â€, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About Global Hemp Group Inc.
Global Hemp Group Inc. (CSE: GHG) (OTC: GBHPF) (FRANKFURT: GHG), is headquartered in Vancouver, British Columbia, Canada, with base operations in Montreal and Los Angeles. The Company is focused on a multi-phased strategy to build a strong presence in the industrial hemp industry in both Canada and the United States. The first phase of this strategy is to develop hemp cultivation with the objective of extracting cannabinoids (CBD, CBG, CBN & CBC) and creating a near term revenue stream that will allow the Company to expand and develop successive phases of the strategy. The second phase of the plan will focus on the development of value-added industrial hemp products utilizing the processing of the whole hemp plant, as envisioned in the Company’s Hemp Agro-Industrial Zone (HAIZ) strategy.

Forward Looking Statements
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWires/MCOA

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]